⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 7, 2024The Journal of Headache and PainOpen Access

Post-marketing safety concerns with rimegepant based on a pharmacovigilance study

Jialing Hu Jing-Ying Wu Shan Xu Shi-Yan Qian Cheng Jiang Guo‐qing Zheng

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

This study aimed to comprehensively assess the safety of rimegepant administration in real-world clinical settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/68e55b65e2b3180350ef925b https://doi.org/10.1186/s10194-024-01858-4

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States2024 · 8 citations
2A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine2024 · 49 citations
3RIMEGEPANT AS A NOVEL THERAPEUTIC OPTION FOR MIGRAINE: A SYSTEMATIC REVIEW OF SAFETY AND TOLERABILITYSystematic Review · 2026
4Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study2024 · 5 citations
5Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study2024 · 19 citations

Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine2026
A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention2025
The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open‐label, single‐dose, parallel‐group study2025
Migraine and depression risk in women: integrated evidence from the global burden of disease, UK Biobank, and Mendelian randomizationThe Journal of Headache and Pain · 2026
Prevalence, disability, and psychosocial correlates of headache disorders among palestinian school-aged adolescents: a cross-sectional studyThe Journal of Headache and Pain · 2026

More from The Journal of Headache and Pain

More from Zhejiang Chinese Medical University

More from Tongde Hospital of Zhejiang Province